2. Academic Validation
  3. Structure-based discovery of sulfamoyl-ethyl-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine amides and sulfonamides as potent B-Cell Lymphoma 6 (BCL6)-BTB inhibitors

Structure-based discovery of sulfamoyl-ethyl-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine amides and sulfonamides as potent B-Cell Lymphoma 6 (BCL6)-BTB inhibitors

  • Bioorg Med Chem Lett. 2026 Feb 1:131:130471. doi: 10.1016/j.bmcl.2025.130471.
Ahmed Mamai 1,  Mohammed M Morshed 2,  Michael Prakesch 2,  Gennady Poda 3,  Pandiaraju Subramanian 2,  Anh M Chau 2,  Iain D G Watson 2,  Babu Joseph 2,  Brian Wilson 2,  Justin A Morin 2,  Richard Marcellus 2,  Brigitte Theriault 2,  Mohammed Mohammed 2,  Ayome Abibi 2,  Manuel Chan 2,  Taira Kiyota 2,  Ahmed Aman 3,  Ratheesh Subramaniam 2,  Craig Strathdee 2,  Jeffrey Winston 2,  Jeff O'Meara 2,  Doug Kuntz 4,  Neil C Pomroy 4,  David Uehling 2,  Methvin Isaac 2,  Gilbert G Privé 4,  Rima Al-Awar 5
Affiliations

Affiliations

  • 1 Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada. Electronic address: amamai@oicr.on.ca.
  • 2 Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada.
  • 3 Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
  • 4 Department of Medical Biophysics, University of Toronto, and Princess Margaret Cancer Centre, Toronto, ON M5S 1A8, Canada.
  • 5 Drug Discovery Program, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario M5G 0A3, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada; Department of Chemistry, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: ralawar@oicr.on.ca.
PMID: 41241078 DOI: 10.1016/j.bmcl.2025.130471
Abstract

Diffuse Large B-Cell Lymphoma (DLBCL) is one of the most aggressive forms of lymphoid malignancies. About 40 % of patients eventually relapse and succumb to the disease within 5 years after diagnosis, underscoring the need for new treatment modalities. B-Cell Lymphoma 6 protein (BCL6) is a repressive transcription factor that is dysregulated in about 40 % of DLBCLs. As a rationale for pursuing BCL6 as a drug target, disrupting complexes between this protein and its co-repressors is thought to mitigate the downstream oncogenic effects of this pathway. However, drugging transcription factors presents a formidable undertaking since targeting protein-protein interactions has historically been challenging. In this study, we used X-ray structures of BCL6-SMRT (a silencing mediator for retinoid or thyroid-hormone receptors, also known as the nuclear receptor co-repressor 2, NCOR2) peptide and compound 79-6 to conduct a virtual screen of a library of 5.2 million compounds. Through this exercise, we identified the pyrrolopyridone 3 as a viable hit, which in turn led to the identification of pyrrolopyrimidone lead compound 4. The X-ray crystal structure of 4 bound to the BTB (Broad-Complex, Tramtrack, and Bric à brac) domain of BCL6 revealed a large back pocket as well as a left-hand channel adjacent to the ligand that could be leveraged to optimize these compounds. Sulfonamide side chains were therefore introduced to target this space, leading to compounds 11d and 11e having sub-micromolar binding to the BTB domain of BCL6.

Keywords

BCL6; DLBCL lymphoma; Heck; Protein–protein interaction; Sulfonamide.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-180166
    BCL6抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z